C-Rad ABLTS:0R44 87 Gross Margin % is 73.16% as of Mar. 2026, which is 15% above its 10-year median of 63.76. GuruFocus rates LTS:0R44 with a GF Score™ of 87/100 and a GF Value™ of kr33.48 (Fairly Valued). The stock has 4 warning signs investors should review. Among 805 Medical Devices & Instruments companies, C-Rad AB ranks better than 82.86% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. C-Rad AB's Gross Profit for the
three
months ended in Mar. 2026 was kr76.6 Mil. C-Rad AB's Revenue for the
three
months ended in Mar. 2026 was kr104.7 Mil. Therefore, C-Rad AB's Gross Margin % for the quarter that ended in Mar. 2026 was 73.16%.
The historical rank and industry rank for C-Rad AB's Gross Margin % or its related term are showing as below:
LTS:0R44'
s Gross Margin % Range Over the Past 10 Years
Min: 59.73 Med: 63.76 Max: 71.91
Current: 71.91
During the past 13 years, the highestGross Margin % of C-Rad AB was 71.91%. The lowest was 59.73%. And the median was 63.76%.
LTS:0R44's Gross Margin % is ranked better than 82.86% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 51.94
vs LTS:0R44: 71.91
C-Rad AB had a gross margin of 73.16% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for C-Rad AB was 2.60% per year.
C-Rad AB (LTS:0R44) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
C-Rad AB had a gross margin of 73.16% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
C-Rad AB Gross Margin % Related Terms
C-Rad AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for C-Rad AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R44 vs ABT, SYK, MDT: Gross Margin % Comparison
For the Medical Devices subindustry, C-Rad AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-Rad AB Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where C-Rad AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
C-Rad AB (LTS:0R44) has a Gross Margin % of 73.16% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on C-Rad AB and its competitors. This is 15% above median its historical median of 63.76. Over the past decade, C-Rad AB's Gross Margin % has ranged from 59.73 to 71.91. According to the industry distribution chart, C-Rad AB ranks #138 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 17.1%.
Is C-Rad AB's Gross Margin % too high?
C-Rad AB's current Gross Margin % of 73.16% is 15% above median its 10-year median of 63.76. Over the past 10 years, this metric has ranged from a low of 59.73 to a high of 71.91. The Medical Devices & Instruments industry median Gross Margin % is 51.94. C-Rad AB's value of 73.16% is 40.9% above this industry median. Based on the distribution chart, C-Rad AB ranks #138 out of 805 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, C-Rad AB has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, C-Rad AB ranks #138 out of 805 companies for Gross Margin %. This places C-Rad AB in the top 17% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 51.94. C-Rad AB's value of 73.16% is 40.9% above this benchmark. Historically, C-Rad AB's own Gross Margin % has ranged from 59.73 to 71.91 over the past decade. While the company's 10-year median is 63.76 vs. the industry median of 51.94, C-Rad AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 51.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-Rad AB's current Gross Margin % of 73.16% is 40.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on C-Rad AB and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 51.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-Rad AB's current Gross Margin % is 73.16%, which is 15% above median its own 10-year median of 63.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Fairly Valued. The stock's GF Value™ is kr33.48, compared to a current price of kr35.90 — trading 7.2% above its estimated fair value. The current Gross Margin % is 73.16%, which is 15% above median its 10-year median of 63.76 and 40.9% above the Medical Devices & Instruments industry median of 51.94. C-Rad AB's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current Gross Margin % is 73.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-Rad AB (LTS:0R44) Overvalued in 2026?
Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued.
The current stock price of kr35.90 is trading 7.2% above its estimated GF Value™ of kr33.48.
GuruFocus considers C-Rad AB to be Fairly Valued.
Key valuation signals for LTS:0R44:
Gross Margin %: 73.16% (15% above median its 10-year median of 63.76)
GF Value™: kr33.48 vs. price of kr35.90 (7.2% above fair value)
Industry Position: 40.9% above the Medical Devices & Instruments median (#138 of 805)
No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
87GF Score
Get the complete analysis for LTS:0R44
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R44 has been successfully added to your 
